{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005405","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2026-08-11T11:00:31+00:00","discovered_at":"2026-08-11T11:05:00.328631+00:00","generated_at":"2026-08-11T11:05:22.701767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harvard Bioscience Q2 revenue up 11% to $22.7M; raises FY2026 revenue guidance to 3-5%","bullets":["Q2 2026 revenue $22.7M, up 11% YoY from $20.5M; FX tailwind of ~1% on constant-currency basis","Net loss widened to ($2.9)M from ($2.3)M; adjusted EBITDA up to $1.7M from $1.5M","H1 net loss narrowed to ($6.3)M from ($52.6)M, which included $48.0M Q1 2025 goodwill impairment","Raises FY 2026 revenue guidance to 3%-5% YoY growth; maintains adjusted EBITDA target","Growth driven by telemetry and CMT products (AAA, electroporation) plus China demand; H1 operating cash flow ($0.3)M vs $5.7M"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005405","json":"https://secwatch.observer/filing/0001171843-26-005405.json","markdown":"https://secwatch.observer/filing/0001171843-26-005405.md","text":"https://secwatch.observer/filing/0001171843-26-005405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/0001171843-26-005405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/f8k_081126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:05:22.701767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}